Ajanta Pharma share price
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹3,270.60.
- Next results date: the board meets on 30 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹41,035 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 Jul 2026
- 36.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 5 May 2026
- 9.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.83%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 30 Jul 2026
- 27.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 30 Jul 2026
- 27.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 5 May 2026
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,54,84762.5% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 30 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,626 Crup 14.37%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹334 Crup 25.32%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 20.6%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 30 Oct | Dec 2024Filed 30 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 28 Jul | Sep 2025Filed 3 Nov | Dec 2025Filed 30 Jan | Mar 2026Filed 5 May | Jun 2026Filed 30 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 |
| Net profit | 216 | 233 | 225 | 255 | 260 | 274 | 267 | 334 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 18.2% | 20.3% | 19.2% | 19.6% | 19.2% | 19.9% | 18.8% | 20.6% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 82% of 2,480 trading days over the last 10 years.
At or below today's level on 88% of 1,977 trading days since Nov 2018.
At or below today's level on 87% of 1,977 trading days since Nov 2018.
At or below today's level on 92% of 2,473 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +7.9% | +14.9% | −6.9% | 1.0% |
| 3 years | +33.8% | +22.6% | +8.0% | 1.5% |
| 5 years | +19.7% | +11.0% | +6.8% | 1.1% |
Mutual funds holding it
197 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 80 of the 111 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 4
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 85
- CutCut. Funds that held fewer shares than at the end of the month before.
- 26
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 80
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 5
| Fund | |||
|---|---|---|---|
 Nippon India Small Cap FundNippon India Mutual Fund | 16,74,471 | 0.75% | ₹606.3 Cr |
 Kotak Flexi Cap FundKotak Mahindra Mutual Fund | 16,17,147 | 1.10% | ₹585.5 Cr |
 UTI Flexi Cap FundUTI Mutual Fund | 13,17,224 | 2.12% | ₹476.9 Cr |
| Kotak-Small Cap FundKotak Mahindra Mutual Fund | 10,86,134 | 2.05% | ₹393.3 Cr |
| Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 9,85,144 | 1.17% | ₹356.7 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 9,13,918 | 3.61% | ₹330.9 Cr |
 HDFC Large & Mid Cap FundHDFC Mutual Fund | 8,97,224 | 1.14% | ₹324.9 Cr |
 Canara Robeco Small Cap FundCanara Robeco Mutual Fund | 7,47,040 | 1.94% | ₹270.5 Cr |
| Nippon India Multi Cap FundNippon India Mutual Fund | 7,42,553 | 0.50% | ₹268.9 Cr |
| UTI Mid Cap FundUTI Mutual Fund | 7,07,737 | 2.15% | ₹256.3 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Ajanta Pharma in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Abbott IndiaABBOTINDIA | 53,187 | 32.9 | 11.1 | 25.9 | +6.3% | +11.2% | 35.9% | 39.6% | 2.62% |
 BioconBIOCON | 52,721 | 106.4 | 1.5 | 18.2 | +9.8% | +28.6% | 1.8% | 2.9% | 0.15% |
 IPCA LaboratoriesIPCALAB | 49,556 | 37.8 | 6.1 | 22.3 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Gland PharmaGLAND | 46,645 | 41.3 | 4.5 | 24.9 | +17.6% | +46.5% | 11.6% | 12.4% | 0.71% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 40,737 | 38.1 | 18.0 | 29.1 | +5.8% | +12.4% | 50.6% | 56.3% | 2.37% |
 Emcure PharmaceuticalsEMCURE | 33,586 | 33.2 | 6.8 | 17.5 | +18.4% | +35.9% | 21.5% | 25.2% | 0.20% |
 Sai Life SciencesSAILIFE | 29,639 | 81.9 | 11.9 | 45.0 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 29,276 | 71.6 | 5.9 | 40.4 | +18.4% | – | 8.8% | 7.4% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 5 Aug 2026 | Interim | ₹32.00 |
| 10 Nov 2025 | Interim | ₹28.00 |
| 6 Nov 2024 | Interim | ₹28.00 |
| 8 Feb 2024 | Interim | ₹26.00 |
| 4 Aug 2023 | Interim | ₹10.00 |
| 4 Aug 2023 | Special | ₹15.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
15 Oct · Analysts
Sep 2026
30 Sep · General Updates
Ajanta Pharma share price by year
Each calendar year to 2025.Ajanta Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2,768.90 | −5.6% | 2,998.25 | 2,374.45 |
| 2024 | 2,932.20 | +40.7% | 3,426.50 | 2,064.95 |
| 2023 | 2,083.65 | +71.9% | 2,083.65 | 1,159.95 |
| 2022 | 1,211.95 | −18.7% | 1,543.20 | 1,105.40 |
| 2021 | 1,490.37 | +36.9% | 1,596.47 | 1,099.87 |
| 2020 | 1,088.80 | +67.6% | 1,148.50 | 650.43 |
| 2019 | 649.70 | −17.8% | 787.80 | 587.07 |
| 2018 | 790.47 | −20.5% | 1,059.10 | 607.73 |
| 2017 | 994.30 | −16.3% | 1,229.80 | 753.93 |
| 2016 | 1,188.53 | +33.9% | 1,395.37 | 773.17 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 3,261.40 | 3,349.60 | 3,224.30 | 3,283.90 | 3,289.34 | 1,54,847 | 62.5% |
| 22 Oct 2026 | 3,215.10 | 3,291.20 | 3,199.90 | 3,270.60 | 3,251.76 | 58,123 | 51.5% |
| 21 Oct 2026 | 3,285.00 | 3,314.30 | 3,250.00 | 3,260.20 | 3,263.32 | 53,439 | 70.4% |
| 19 Oct 2026 | 3,325.90 | 3,387.50 | 3,285.00 | 3,298.90 | 3,325.67 | 36,644 | 50.4% |
| 16 Oct 2026 | 3,372.50 | 3,381.00 | 3,308.30 | 3,329.00 | 3,345.03 | 38,358 | 54.4% |
| 15 Oct 2026 | 3,330.00 | 3,387.70 | 3,313.70 | 3,359.40 | 3,355.09 | 1,03,485 | 54.7% |
| 14 Oct 2026 | 3,328.20 | 3,377.20 | 3,269.90 | 3,299.00 | 3,314.62 | 74,868 | 54.4% |
| 13 Oct 2026 | 3,399.40 | 3,413.90 | 3,310.00 | 3,328.20 | 3,350.24 | 52,616 | 74.2% |
| 12 Oct 2026 | 3,405.00 | 3,421.40 | 3,380.90 | 3,399.40 | 3,400.18 | 92,290 | 63.8% |
| 9 Oct 2026 | 3,437.90 | 3,478.20 | 3,364.40 | 3,410.10 | 3,407.03 | 1,24,419 | 59.7% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 22 Jun 2022 | Bonus | 0.6667 | Holders received 1 bonus share for every 2 held. |
| 20 Mar 2015 | Split | 0.4000 | Every 2 shares became 5. |
| 17 Sep 2013 | Bonus | 0.6667 | Holders received 1 bonus share for every 2 held. |
| 9 Aug 2012 | Split | 0.5000 | Each share became 2. |
About Ajanta Pharma
Ajanta Pharma Limited is a specialty pharmaceutical formulation company with its registered office in Mumbai. It was incorporated in 1979. Its shares are listed on BSE Limited and NSE Limited.
The company has four businesses: branded generics in India, branded generics in Asia and Africa, generic medicines in the United States, and an institutional business in Africa. The institutional business sells antimalarial products through multilateral aid agencies. The branded generics portfolio includes more than 600 products, sold in India and in more than 33 emerging market countries in Asia and Africa.
In India, the company reports sales by therapy area, including cardiology, dermatology and ophthalmology, and it serves 28 states and 8 union territories. In Asia it operates in nearly 12 countries across the Middle East, Southeast Asia and Central Asia. In Africa it operates in 21 countries. It also has a presence in 23 further countries through promotional agents, distributors and supervisors, without physical offices there.
The company runs seven manufacturing plants in India, located in Maharashtra, Gujarat, Assam and Madhya Pradesh. Two of its facilities are approved by the US FDA, and all its manufacturing facilities operate with zero liquid discharge systems. A research team of more than 850 scientists develops its products. More than 13,000 people work for the company, which calls them Ajantaites.
The company has five wholly owned overseas subsidiaries, including Ajanta Pharma USA Inc.
- Legal name
- Ajanta Pharma Limited
- NSE symbol
- AJANTPHARM
- BSE code
- 532331
- ISIN
- INE031B01049
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- May 2000 on NSE, Jun 2000 on BSE
- Face value
- ₹2
- CIN
- L24230MH1979PLC022059
- Corporate identity number, the registrar of companies' code for it